I think XXII is nearing its end with Sabby- we will learn more on that soon via filings
They have lots of catalyst- British American milestone payments- clearing out Sabby of course- Pfizer- more licensing agreements- production of their modified risk cig's etc. etc.
just the partner they landed alone should command them a better valuation imo- but they flushed several out recently with Sabby's selling to go with a few small insider sells which didn't help confidence either.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.